Claims for Patent: 9,168,258

Summary for Patent: 9,168,258

Title:	Methods and compositions for sleep disorders and other disorders
Abstract:	Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
Inventor(s):	Mates Sharon, Fienberg Allen, Wennogle Lawrence P.
Assignee:	INTRA-CELLULAR THERAPRIES, INC.
Application Number:	US14066987
Patent Claims:	2. The pharmaceutical composition according to wherein the oral unit dose form is a tablet.3. The pharmaceutical composition according to wherein the oral unit dose form is a capsule.4. The pharmaceutical composition according to wherein the amount of Compound of Formula I is 5 mg.5. The pharmaceutical composition according to wherein the amount of Compound of Formula I is 2.5 mg.7. The pharmaceutical composition according to wherein the Compound of Formula I is in the form of the tosylate salt.8. The pharmaceutical composition according to wherein the amount of Compound of Formula I is 2.5 mg.9. The pharmaceutical composition according to wherein the amount of Compound of Formula I is 3 mg.10. The pharmaceutical composition according to wherein the amount of Compound of Formula I is 4 mg.11. The pharmaceutical composition according to wherein the amount of Compound of Formula I is 5 mg.12. The pharmaceutical composition according to wherein the amount of Compound of Formula I is 10 mg.13. The pharmaceutical composition according to wherein the Compound of Formula I is in the form of the tosylate salt.14. The pharmaceutical composition according to claim 6 , further comprising one or more therapeutic agents selected from the group consisting of compounds that modulate GABA activity claim 6 , a GABAB agonist claim 6 , a 5-HT modulator claim 6 , a melatonin agonist claim 6 , an ion channel modulator claim 6 , a serotonin-2 antagonist/reuptake inhibitor (SARIs) claim 6 , an orexin receptor antagonist claim 6 , an H3 agonist claim 6 , a noradrenergic antagonist claim 6 , a galanin agonist claim 6 , a CRH antagonist claim 6 , human growth hormone claim 6 , a growth hormone agonist claim 6 , estrogen claim 6 , an estrogen agonist claim 6 , a neurokinin-I drug claim 6 , an anti-depressant claim 6 , and an antipsychotic agent claim 6 , in free or pharmaceutically acceptable salt form.15. The pharmaceutical composition according to claim 6 , further comprising one or more therapeutic agents selected from the group consisting of modafinil claim 6 , armodafinil claim 6 , doxepin claim 6 , alprazolam claim 6 , bromazepam claim 6 , clobazam claim 6 , clonazepam claim 6 , clorazepate claim 6 , diazepam claim 6 , flunitrazepam claim 6 , flurazepam claim 6 , lorazepam claim 6 , midazolam claim 6 , nitrazepam claim 6 , oxazepam claim 6 , temazapam claim 6 , triazolam claim 6 , indiplon claim 6 , zopiclone claim 6 , eszopiclone claim 6 , zaleplon claim 6 , Zolpidem claim 6 , gabaxadol claim 6 , vigabatrin claim 6 , tiagabine claim 6 , EVT 201 claim 6 , estazolam claim 6 , ketanserin claim 6 , risperidone claim 6 , eplivanserin claim 6 , volinanserin claim 6 , pruvanserin claim 6 , MDL 100907 claim 6 , HY10275 claim 6 , APD125 claim 6 , AVE8488 claim 6 , repinotan claim 6 , sarizotan claim 6 , eptapirone claim 6 , buspirone claim 6 , MN-305 claim 6 , melatonin claim 6 , ramelteon claim 6 , VEC-162 claim 6 , PD-6735 claim 6 , agomelatine claim 6 , lamotrigine claim 6 , gabapentin claim 6 , pregabalin claim 6 , orexin claim 6 , a 1 claim 6 ,3-biarylurea claim 6 , SB-334867-a claim 6 , GW649868 claim 6 , a benzamide derivative claim 6 , Org 50081 claim 6 , ritanserin claim 6 , nefazodone claim 6 , serzone claim 6 , trazodone claim 6 , Casopitant claim 6 , amitriptyline claim 6 , amoxapine claim 6 , bupropion claim 6 , citalopram claim 6 , clomipramine claim 6 , desipramine claim 6 , doxepin claim 6 , duloxetine claim 6 , escitaloprame claim 6 , fluoxetine claim 6 , fluvoxamine claim 6 , imipramine claim 6 , isocarboxazid claim 6 , maprotiline claim 6 , mirtazapine claim 6 , nefazodone claim 6 , nortriptyline claim 6 , paroxetine claim 6 , phenlzine sulfate claim 6 , protiptyline claim 6 , sertraline claim 6 , tranylcypromine claim 6 , trazodone claim 6 , trimipramine claim 6 , velafaxine claim 6 , chlorpromazine claim 6 , haloperidol claim 6 , droperidol claim 6 , fluphenazine claim 6 , loxapine claim 6 , mesoridazine molidone claim 6 , perphenazine claim 6 , pimozide claim 6 , prochlorperazine promazine claim 6 , thioridazine claim 6 , thiothixene claim 6 , trifluoperazine claim 6 , clozapine claim 6 , aripiparazole claim 6 , olanzapine claim 6 , quetiapine claim 6 , risperidone claim 6 , ziprasidone and paliperidone claim 6 , in free or pharmaceutically acceptable salt form.16. The pharmaceutical composition according to claim 6 , further comprising one or more therapeutic agents selected from the group consisting of L-dopa claim 6 , co-careldopa claim 6 , duodopa claim 6 , stalova claim 6 , symmetrel claim 6 , benzotropine claim 6 , biperiden claim 6 , bromocryiptine claim 6 , entacapone claim 6 , pergolide claim 6 , pramipexole claim 6 , procyclidine claim 6 , ropinirole claim 6 , selegiline and tolcapone.17. The pharmaceutical composition according to wherein the amount of Compound of Formula I is 2.5 mg.18. The pharmaceutical composition according to wherein the amount of Compound of Formula I is 5 mg.19. The pharmaceutical composition according to wherein the amount of Compound of Formula I is 2.5 mg.20. The pharmaceutical composition according to wherein the amount of Compound of Formula I is 5 mg.